Ondine Biomedical Inc Cash Flow Conversion Efficiency

Latest as of June 2026: 4.082x

Ondine Biomedical Inc cash flow conversion efficiency. Based on the latest financial reports, Ondine Biomedical Inc (OBI) has a cash flow conversion efficiency ratio of 4.082x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-13.16 Million ≈ $-1.60K USD) by net assets (GBX-3.22 Million ≈ $-392.23 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Ondine Biomedical Inc (2001–2025)

Cash flow conversion efficiency of Ondine Biomedical Inc from 2001 to 2025. This chart illustrates how Ondine Biomedical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View OBI stock price and chart for real-time trading data and today's change.

Ondine Biomedical Inc Cash Flow Conversion Ratio Explained

Ondine Biomedical Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Ondine Biomedical Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ondine Biomedical Inc ranked by their cash flow conversion efficiency. Also see Ondine Biomedical Inc stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Ivory Properties Group Bhd KLSE:5175	0.629x
FRNT Financial Inc V:FRNT	-0.111x
Town Centre Securities PLC LSE:TOWN	0.032x
Moolec Science SA Ordinary Shares NASDAQ:MLEC	-0.059x
Enersize Oy ST:ENERS	0.057x
Flowtech Fluidpower plc LSE:FLO	-0.022x
IO Biotech Inc NASDAQ:IOBT	-20.283x
Panther Securities P L C LSE:PNS	0.008x

Annual Cash Flow Conversion Efficiency for Ondine Biomedical Inc (2001–2025)

The table below shows the annual cash flow conversion efficiency of Ondine Biomedical Inc from 2001 to 2025. Review OBI cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	GBX3.49 Million ≈ $424.53	GBX-23.90 Million ≈ $-2.91K	-6.851x	-204.17%
2024-12-31	GBX6.88 Million ≈ $836.73	GBX-15.49 Million ≈ $-1.88K	-2.252x	+65.60%
2023-12-31	GBX2.08 Million ≈ $253.68	GBX-13.65 Million ≈ $-1.66K	-6.548x	-366.49%
2022-12-31	GBX11.64 Million ≈ $1.42K	GBX-16.34 Million ≈ $-1.99K	-1.404x	-231.98%
2021-12-31	GBX29.66 Million ≈ $3.61K	GBX-12.54 Million ≈ $-1.53K	-0.423x	-325.93%
2020-12-31	GBX-33.83 Million ≈ $-4.12K	GBX-6.33 Million ≈ $-770.30	0.187x	-35.38%
2019-12-31	GBX-26.07 Million ≈ $-3.17K	GBX-7.55 Million ≈ $-918.74	0.290x	-48.60%
2018-12-31	GBX-17.90 Million ≈ $-2.18K	GBX-10.08 Million ≈ $-1.23K	0.563x	-29.97%
2017-12-31	GBX-6.55 Million ≈ $-796.70	GBX-5.27 Million ≈ $-640.96	0.805x	+108.26%
2010-12-31	GBX279.19K ≈ $33.97	GBX-2.72 Million ≈ $-330.96	-9.743x	-262.05%
2009-12-31	GBX1.28 Million ≈ $155.48	GBX-3.44 Million ≈ $-418.39	-2.691x	+59.70%
2008-12-31	GBX1.34 Million ≈ $162.71	GBX-8.93 Million ≈ $-1.09K	-6.677x	-508.20%
2007-12-31	GBX10.84 Million ≈ $1.32K	GBX-11.90 Million ≈ $-1.45K	-1.098x	-67.96%
2006-12-31	GBX16.59 Million ≈ $2.02K	GBX-10.84 Million ≈ $-1.32K	-0.654x	-28.61%
2005-12-31	GBX16.50 Million ≈ $2.01K	GBX-8.39 Million ≈ $-1.02K	-0.508x	-274.72%
2003-08-31	GBX-227.62K ≈ $-27.70	GBX-66.20K ≈ $-8.06	0.291x	+264.97%
2002-08-31	GBX-143.28K ≈ $-17.43	GBX25.26K ≈ $3.07	-0.176x	-396.57%
2001-08-31	GBX1.39 Million ≈ $169.63	GBX-49.50K ≈ $-6.02	-0.036x	--

About Ondine Biomedical Inc

LSE:OBI UK Biotechnology

Market Cap

$614.56K

GBX5.05 Billion GBX

Market Cap Rank

#30957 Global

#885 in UK

Share Price

GBX9.00

Change (1 day)

-4.76%

52-Week Range

GBX8.00 - GBX15.40

All Time High

GBX58.50